1. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women JAMA. 1998;280(7):605-613. doi:10.1001/jama.280.7.605 Figure 1.—The Heart and Estrogen/progestin Replacement Studytrial profile, showing numbers of participants from screening to closeout. Figure Legend:

2. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women JAMA. 1998;280(7):605-613. doi:10.1001/jama.280.7.605 Figure 2.—Participants taking protocol medications and withpill count of 80% or more, as a percentage of all women at risk for a primarycoronary heart disease event. Figure Legend:

3. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women JAMA. 1998;280(7):605-613. doi:10.1001/jama.280.7.605 Figure 3.—Kaplan-Meier estimates of the cumulative incidenceof primary coronary heart disease (CHD) events (left) and to its constituents:nonfatal myocardial infarction (MI) (center) and CHD death (right). The numberof women observed at each year of follow-up and still free of an event areprovided in parentheses, and the curves become fainter when this number dropsbelow half of the cohort. Log rank P values are.91for primary CHD events,.46 for nonfatal MI, and.23 for CHD death. Figure Legend:

4. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women JAMA. 1998;280(7):605-613. doi:10.1001/jama.280.7.605 Figure 4.—Kaplan-Meier estimate of the cumulative incidenceof definite unstable angina or coronary artery bypass graft or percutaneouscoronary revascularization. The number of women observed at each year of follow-upand still free of an event are provided in parentheses, and the curves becomefainter when this number drops below half the cohort. Log rank P value is.15. Figure Legend:

5. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women JAMA. 1998;280(7):605-613. doi:10.1001/jama.280.7.605 Figure 5.—Mean change in low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride levelsduring the first year of the study, expressed as percent change ± SEM. Figure Legend:

6. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women JAMA. 1998;280(7):605-613. doi:10.1001/jama.280.7.605 Figure 6.—Kaplan-Meier estimate of cumulative incidence ofdeath from any cause. The number of women observed at each year of follow-upand still free of an event are provided in parentheses, and the curves becomefainter when this number drops below half of the cohort. Log rank P value is.56. Figure Legend: